已收盤 01-30 16:00:00 美东时间
+1.020
+1.03%
One of the lessons that has stayed with me through decades of bull markets, bea...
01-30 00:15
今日重点评级关注:Piper Sandler:维持Praxis Precision Medicine"超配"评级,目标价从450美元升至1200美元;Tigress Financial:维持Main International ETF"买入"评级,目标价从52美元升至66美元
01-29 11:06
今日重点评级关注:瑞穗:维持Syndax制药"跑赢大市"评级,目标价从410美元升至600美元;HC Wainwright & Co.:维持60 Degrees Pharmaceuticals, Inc."买入"评级,目标价从6美元升至24美元
01-28 10:59
今日重点评级关注:RBC Capital:维持Compass Pathways"跑赢大市"评级,目标价从16美元升至21美元;RBC Capital:维持GH Research"跑赢大市"评级,目标价从33美元升至40美元
01-26 14:32
Morgan Stanley analyst Devin McDermott maintains Chord Energy (NASDAQ:CHRD) with a Equal-Weight and lowers the price target from $123 to $114.
01-24 01:08
今日重点评级关注:HC Wainwright & Co.:维持Rezolve AI"买入"评级,目标价从10美元升至12美元;HC Wainwright & Co.:维持Largo"买入"评级,目标价从2.9美元升至3.1美元
01-15 16:10
今日重点评级关注:HC Wainwright & Co.:维持NioCorp Developments"买入"评级,目标价从9.5美元升至11.25美元;摩根士丹利:维持Chewy"超配"评级,目标价从48美元升至51美元
01-14 11:25
今日重点评级关注:Needham:维持Cartesian Therapeutics"买入"评级,目标价从40美元升至42美元;Piper Sandler:维持Acrivon Therapeutics"超配"评级,目标价从6美元升至8美元
01-12 14:09
UBS analyst Josh Silverstein maintains Chord Energy (NASDAQ:CHRD) with a Buy and lowers the price target from $123 to $119.
01-10 00:35
今日重点评级关注:杰富瑞:维持ImmunityBio Inc Ordinary Shares"买入"评级,目标价从8美元升至9美元;B. Riley证券:维持WAVE Life Sciences"买入"评级,目标价从19美元升至37美元
2025-12-15 15:30